Immune cells in the bone marrow microenvironment of AML patients are key in distinguishing a response to immunotherapy.

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte ... myeloid leukemia (AML) who have relapsed after allogenic hematopoietic stem cell ...

Dana-Farber researchers identified factors predicting the success of donor lymphocyte infusion (DLI) in treating relapsed AML. They found that specific CD8+ T cells with high ZNF683/Hobit expression ...

Discover how groundbreaking research on unique immune cells and advanced AI tools offers renewed hope for improving cancer ...

Boston – Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who ...

This site uses cookies to enhance your user experience. By continuing to use this site you are agreeing to our COOKIE POLICY.

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have ...

Blood tests often show a high white blood cell or lymphocyte level. You’d get more tests to find out if this is leukemia. Two other types of leukemia -- acute myeloid leukemia (AML) and chronic ...

A research team from Columbia Engineering and the Irving Institute for Cancer Dynamics achieved a significant finding in ...